Liver Cirrhosis Research Today is a free monthly online journal that collates and summarizes the latest research about Liver Cirrhosis, including details on alcohol, treatment, drugs, effects, causes.

Volume 5 (2008), Issue 2 (February)

1. A predictive model for fatigue and its etiologic associations in primary biliary cirrhosis.
   Clin Gastroenterol Hepatol, 6(2): 228-33. [Abstract] [Full-text]
2. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C.
   Clin Gastroenterol Hepatol, 6(2): 242-7. [Abstract] [Full-text]
3. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.
   Gastroenterology, 134(2): 416-23. [Abstract] [Full-text]
4. Continuous high expression of XBP1 and GRP78 is important for the survival of bone marrow cells in CCl4-treated cirrhotic liver.
   Biochem Biophys Res Commun, 367(3): 546-52. [Abstract] [Full-text]
5. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
   Hepatology, 47(2): 605-12. [Abstract] [Full-text]
6. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage.
   Hepatology, 47(2): 592-5. [Abstract] [Full-text]
7. The causes of primary biliary cirrhosis: Convenient and inconvenient truths.
   Hepatology, 47(2): 737-45. [Abstract] [Full-text]
8. Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis.
   Hepatology, 47(2): 571-80. [Abstract] [Full-text]
9. Acute viral hepatitis increases liver stiffness values measured by transient elastography.
   Hepatology, 47(2): 380-4. [Abstract] [Full-text]
10. Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis.
    Hepatology, 47(2): 563-70. [Abstract] [Full-text]
11. Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis.
    Hepatology, 47(2): 625-35. [Abstract] [Full-text]
12. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Clin Infect Dis, 46(5): 768-74. [Abstract] [Full-text]
13. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.
    Am J Med, 121(2): 119-26. [Abstract] [Full-text]
14. Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo.
    Gut, 57(3): 352-64. [Abstract] [Full-text]
15. Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers.
    J Pharmacol Exp Ther, 324(3): 902-10. [Abstract] [Full-text]
16. A novel synthetic oleanolic acid derivative (CPU-II2) attenuates liver fibrosis in mice through regulating the function of hepatic stellate cells.
    J Biomed Sci, 15(2): 251-9. [Abstract] [Full-text]
17. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
    Aliment Pharmacol Ther, 27(7): 542-51. [Abstract] [Full-text]
18. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis.
    J Viral Hepat, 15(4): 246-9. [Abstract] [Full-text]
19. Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging--initial experience.
    Radiology, 246(3): 926-34. [Abstract] [Full-text]

© 2004-2008 Liver Cirrhosis Research Today. All Rights Reserved.